AzTrials
AzTrials

Survival to Discharge With Good Neurologic Outcome Among in Hospital Cardiac Arrest PatientsNCT07899645

Therapeutic Outcomes of In-Hospital Resuscitation of Patients Admitted to the Internal Medicine Wards

An observational study of Survival to Discharge With Good Neurologic Outcome Among in Hospital Cardiac Arrest Patients, run by Meir Medical Center.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

In-hospital cardiac arrest is a common phenomenon associated with high mortality rates. In the United States, 290,000 cases of in-hospital cardiac arrest among adult patients occur annually (1). The mean patient age is 66 years, and 58% are male. Read more about this study

Who is it for?
Ages 18 to 99 years
How many people
2,000 participants
Where
No sites listed yet
Study dates
1 Jan 2027to 1 Jan 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Adult, Older adult

Study population: All patients aged 18-99 who underwent resuscitation during their hospitalization in the Department of Internal Medicine at Meir Hospital between January 2017 and October 2026.

Inclusion Criteria:All patients aged 18-99 who underwent resuscitation during their hospitalization in the Department of Internal Medicine at Meir Hospital between January 2017 and October 2026.

-

Exclusion Criteria: Patients who underwent resuscitation during hospitalization in wards other than internal medicine departments, or for whom data is missing.

-

About this study

Official title: Therapeutic Outcomes of In-Hospital Resuscitation of Patients Admitted to the Internal Medicine Wards: A Retrospective Study

In-hospital cardiac arrest is a common phenomenon associated with high mortality rates. In the United States, 290,000 cases of in-hospital cardiac arrest among adult patients occur annually (1). The mean patient age is 66 years, and 58% are male. In the majority of cases (81%), the initial cardiac rhythm was non-shockable (asystole, PEA). The primary cause of arrest was cardiac (50-60%), followed by respiratory causes (15-40%) (1). Survival rates for these patients have risen over the past two decades; according to the GWTG-R registry, survival to hospital discharge was 25% in 2017, with 85% of survivors demonstrating a favorable neurological outcome (CPC score of 1 or 2; see details under "Objectives"). It is important to note that these figures vary across different countries, potentially due to differences in the patient populations studied (e.g., survival odds are better for cardiac-related arrest than for respiratory-related arrest; distinctions between internal medicine, surgical, cardiac, and trauma patients; the location of resuscitation-ICU vs. general ward, etc.) as well as cultural, social, and religious factors (e.g., awareness of DNR/DNI orders among the public and medical staff, specific national legislation, and patient preferences). ...the patient and their family regarding end-of-life care due to religious, cultural, or social reasons, etc.).

The GO FAR score (Good Outcome Following Attempted Resuscitation) is a clinical prediction tool that estimates the likelihood of survival to hospital discharge with a good neurological outcome (CPC score of 1) for patients who have undergone in-hospital resuscitation. This score was developed using data from 51,000 patients across 366 hospitals, based on the GWTG-R registry. It incorporates data known prior to cardiac arrest, enabling the medical team, the patient, and the family to formulate a plan in advance regarding the course of action should the patient experience in-hospital cardiac arrest. The data points include age, neurological status upon admission, multisystem trauma, acute stroke, hematologic-oncologic disease or metastatic cancer, sepsis with bacteremia, non-cardiac reason for admission, liver failure, admission from a nursing facility, hypotension or shock upon admission, renal failure, respiratory failure, and pneumonia upon admission. Subsequently, the GO FAR 2 score was developed; while it included the same data points, it slightly modified the scoring method and also incorporated a CPC score of 2 (2,3).

We aim to examine survival rates to discharge with a good neurological outcome following in-hospital resuscitation... At Meir Hospital, we are focusing on a specific patient population: those hospitalized in internal medicine wards. This group generally has a lower likelihood of surviving with intact neurological function (due to factors such as advanced age, non-cardiac causes of arrest, and parameters contributing to a "GO FAR" score that reflects a poor prognosis). Our working hypothesis is that the success rate of resuscitation for these patients is typically very low; attempting it may cause suffering to the patient and their family without offering a reasonable chance of survival with a favorable neurological outcome. Beyond this point-which we consider paramount for the patient-resuscitation attempts with poor prospects entail other consequences: financial costs, extended hospital stays, increased workload for medical and nursing staff, and reduced resource availability for other patients with better recovery prospects, among others. Carefully selecting patients with a higher likelihood of successful in-hospital resuscitation would not only improve outcomes but also prevent unnecessary suffering. To formulate a plan for the informed selection of these patients, this study aims to collect relevant data.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. survival to discharge

    The precentage of patients who underwent in hospital cardiac arrest and survived to hopsital discharge

    Measured: One year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2026
  2. Study start1 Jan 2027 (estimated)
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
2,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07899645
Sponsor's protocol ID
MMC-0413-26
Status last verified
Oct 2026
First submitted
14 Oct 2026
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Survival to Discharge With Good Neurologic Outcome Among in Hospital Cardiac Arrest Patients, run by Meir Medical Center.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

survival to discharge (time frame: One year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in